Bristol-Myers Squibb (BMY) Stock Forecast & Price Target

$52.48

-0.96 (-1.80%)

(As of 10/8/2024 ET)

Bristol-Myers Squibb - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 16 Analyst Ratings

Sell
2

Hold
13

Buy
1

Based on 16 Wall Street analysts who have issued ratings for Bristol-Myers Squibb in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 16 analysts, 2 have given a sell rating, 13 have given a hold rating, and 1 has given a buy rating for BMY.

Consensus Price Target

$53.43
1.81% Upside

According to the 16 analysts' twelve-month price targets for Bristol-Myers Squibb, the average price target is $53.43. The highest price target for BMY is $69.00, while the lowest price target for BMY is $43.00. The average price target represents a forecasted upside of 1.81% from the current price of $52.48.

Get the Latest News and Ratings for BMY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Bristol-Myers Squibb and its competitors.

BMY Analyst Ratings Over Time

Type	Current Forecast 10/9/23 to 10/8/24	1 Month Ago 9/9/23 to 9/8/24	3 Months Ago 7/11/23 to 7/10/24	1 Year Ago 10/9/22 to 10/9/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)	6 Buy rating(s)
Hold	13 Hold rating(s)	13 Hold rating(s)	15 Hold rating(s)	8 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$53.43	$54.67	$59.88	$69.50
Forecasted Upside	1.81% Upside	12.25% Upside	45.65% Upside	22.78% Upside
Consensus Rating	Reduce	Hold	Hold	Hold

[SHOCKING] Crypto Document Leak… (Ad)

Imagine if you could go back to 2009 and buy Bitcoin at $0.01. Or jump to 2015 and grab Ethereum at $0.75. We've created the next best thing: It's called "Crypto Revolution," and it's not just a book… it's your potential ticket to financial time travel.

Download your digital copy of "Crypto Revolution" now (limited-time offer).

BMY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BMY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Bristol-Myers Squibb Stock vs. The Competition

Type	Bristol-Myers Squibb	Medical Companies	S&P 500
Consensus Rating Score	1.94	2.78	2.50
Consensus Rating	Reduce	Moderate Buy	Hold
Predicted Upside	1.19% Upside	10,819.51% Upside	7.88% Upside
News Sentiment Rating	Positive News See Recent BMY News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/7/2024	Barclays 3 of 5 stars	C. Gould Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Underweight ➝ Underweight	$42.00 ➝ $43.00	-20.25%
10/7/2024	TD Cowen 4 of 5 stars		Boost Target	Hold ➝ Hold	$53.00 ➝ $59.00	+9.32%
9/23/2024	BMO Capital Markets 4 of 5 stars		Reiterated Rating	Market Perform ➝ Market Perform	$48.00 ➝ $48.00	-3.17%
9/16/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$50.00 ➝ $50.00	+0.70%
8/28/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$49.00 ➝ $51.00	+3.91%
7/23/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$53.00 ➝ $45.00	+5.36%
Get the Latest News and Ratings for BMY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Bristol-Myers Squibb and its competitors with MarketBeat's FREE daily newsletter.
4/18/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$51.00 ➝ $52.00	+8.11%
4/1/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Phipps Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
3/11/2024	Societe Generale Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
2/6/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$77.00 ➝ $54.00	+12.50%
1/3/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$68.00 ➝ $60.00	+13.67%
11/2/2023	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$68.00 ➝ $54.00	+5.30%
10/30/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$81.00 ➝ $69.00	+35.48%
10/27/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Underweight ➝ Underweight	$56.00 ➝ $50.00	-5.63%
10/27/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Reduce ➝ Hold	$55.00 ➝ $53.00	+0.03%
10/20/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$70.00 ➝ $60.00	+6.29%
10/6/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$84.00	+47.91%
7/28/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight	$90.00 ➝ $85.00	+39.89%
7/12/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$72.00 ➝ $66.00	+5.13%
7/10/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
7/10/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$66.00	+5.35%
4/28/2023	51job Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
10/10/2022	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:33 PM ET.

Should I Buy Bristol-Myers Squibb Stock? BMY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, October 1, 2024. Please send any questions or comments about these Bristol-Myers Squibb pros and cons to contact@marketbeat.com.

Bristol-Myers Squibb
Bull Case

Here are some ways that investors could benefit from investing in Bristol-Myers Squibb:

Bristol-Myers Squibb has a strong portfolio of biopharmaceutical products targeting various diseases such as hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience.
The company has been actively discovering, developing, and licensing new products, indicating a commitment to innovation and growth.
Recent developments in the company's pipeline show promising results in clinical trials, potentially leading to new revenue streams.
Bristol-Myers Squibb's stock price has shown resilience and growth in recent periods, reflecting positive investor sentiment.
The company's global presence and distribution network provide opportunities for expansion into new markets and increased revenue.

Bristol-Myers Squibb
Bear Case

Investors should be bearish about investing in Bristol-Myers Squibb for these reasons:

While the company has a diverse product portfolio, it also faces competition from other pharmaceutical companies in the market.
Regulatory challenges and changes in healthcare policies could impact Bristol-Myers Squibb's operations and profitability.
Market volatility and economic uncertainties may affect the company's stock performance and investor confidence.
Investing in biopharmaceutical companies carries inherent risks related to clinical trial outcomes, regulatory approvals, and market acceptance of new products.
Fluctuations in currency exchange rates and geopolitical factors could impact Bristol-Myers Squibb's international operations and financial results.

BMY Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Bristol-Myers Squibb is $53.43, with a high forecast of $69.00 and a low forecast of $43.00.
: 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last twelve months. There are currently 2 sell ratings, 13 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" BMY shares.
: According to analysts, Bristol-Myers Squibb's stock has a predicted upside of 1.81% based on their 12-month stock forecasts.
: Over the previous 90 days, Bristol-Myers Squibb's stock had 1 downgrade by analysts.
: Bristol-Myers Squibb has been rated by research analysts at Barclays, BMO Capital Markets, Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, and TD Cowen in the past 90 days.
: Analysts like Bristol-Myers Squibb less than other "medical" companies. The consensus rating for Bristol-Myers Squibb is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BMY compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

[SHOCKING] Crypto Document Leak… (Ad)

The crypto market waits for no one. And my team of experts and I believe that a BIG move is right around the corner. That's why we're offering you instant access to the game-changing book that's transforming average investors into massive crypto successes.

Download your digital copy now

This page (NYSE:BMY) was last updated on 10/8/2024 by MarketBeat.com Staff

From Our Partners